diphosphoric acid has been researched along with Calcinosis in 23 studies
diphosphoric acid : An acyclic phosphorus acid anhydride obtained by condensation of two molecules of phosphoric acid.
Calcinosis: Pathologic deposition of calcium salts in tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These hereditary disorders, caused by mutations in genes encoding ATP binding cassette subfamily C member 6, ectonucleotide pyrophosphatase/phosphodiesterase 1, CD73, progressive ankylosis protein, and lamin A/C proteins, respectively, are inorganic pyrophosphate (PPi) deficiency syndromes with reduced circulating levels of PPi, the principal physiologic inhibitor of calcium hydroxyapatite deposition in soft connective tissues." | 9.22 | Inorganic Pyrophosphate Deficiency Syndromes and Potential Treatments for Pathologic Tissue Calcification. ( Li, Q; Ralph, D; Uitto, J; van de Wetering, K, 2022) |
| "Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to that of gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind research in these other forms of arthritis." | 8.31 | Patient-Reported Outcomes in Calcium Pyrophosphate Deposition Disease Compared to Gout and Osteoarthritis. ( Altwies, H; Hayashi, K; Tedeschi, SK; Whelan, MG, 2023) |
| " These hereditary disorders, caused by mutations in genes encoding ATP binding cassette subfamily C member 6, ectonucleotide pyrophosphatase/phosphodiesterase 1, CD73, progressive ankylosis protein, and lamin A/C proteins, respectively, are inorganic pyrophosphate (PPi) deficiency syndromes with reduced circulating levels of PPi, the principal physiologic inhibitor of calcium hydroxyapatite deposition in soft connective tissues." | 5.22 | Inorganic Pyrophosphate Deficiency Syndromes and Potential Treatments for Pathologic Tissue Calcification. ( Li, Q; Ralph, D; Uitto, J; van de Wetering, K, 2022) |
| "Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to that of gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind research in these other forms of arthritis." | 4.31 | Patient-Reported Outcomes in Calcium Pyrophosphate Deposition Disease Compared to Gout and Osteoarthritis. ( Altwies, H; Hayashi, K; Tedeschi, SK; Whelan, MG, 2023) |
| "Pyrophosphate deficiency may explain the excessive vascular calcification found in children with Hutchinson-Gilford progeria syndrome (HGPS) and in a mouse model of this disease." | 3.91 | ATP-based therapy prevents vascular calcification and extends longevity in a mouse model of Hutchinson-Gilford progeria syndrome. ( Villa-Bellosta, R, 2019) |
| "Calcinosis was frequently detected (40% of US and 46% of the Hungarian cohort)." | 1.72 | Inorganic pyrophosphate is reduced in patients with systemic sclerosis. ( Aren, K; Bálint, L; Bocskai, M; Carns, M; Goldberg, I; Hsu, VM; Kovács, L; Kozák, E; Li, Q; McClure, ST; Rosenthal, A; Schlesinger, N; Szamosi, S; Szücs, G; Váradi, A; Varga, J, 2022) |
| "Pyrophosphate (PPi) is a potent inhibitor of ectopic mineralization but its role during aortic valve calcification is not known." | 1.40 | Extracellular pyrophosphate is reduced in aortic interstitial valve cells acquiring a calcifying profile: implications for aortic valve calcification. ( Bertacco, E; Buso, G; Causin, V; D'Andrea, S; Faggin, E; Gerosa, G; Iop, L; Pauletto, P; Puato, M; Rattazzi, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 12 (52.17) | 2.80 |
| Authors | Studies |
|---|---|
| Szeri, F | 5 |
| Niaziorimi, F | 4 |
| Donnelly, S | 2 |
| Fariha, N | 1 |
| Tertyshnaia, M | 1 |
| Patel, D | 1 |
| Lundkvist, S | 5 |
| van de Wetering, K | 7 |
| Ralph, D | 1 |
| Uitto, J | 1 |
| Li, Q | 2 |
| Caffet, M | 3 |
| Terry, SF | 3 |
| Johansson, G | 3 |
| Jansen, RS | 4 |
| Mori, A | 1 |
| Saito, Y | 1 |
| Nakamura, K | 1 |
| Iida, T | 1 |
| Akagi, S | 1 |
| Yoshida, M | 1 |
| Taniyama, M | 1 |
| Miyoshi, T | 1 |
| Ito, H | 1 |
| Whelan, MG | 1 |
| Hayashi, K | 1 |
| Altwies, H | 1 |
| Tedeschi, SK | 1 |
| Kang, M | 1 |
| Wu, M | 1 |
| Crane, JL | 1 |
| Villa-Bellosta, R | 1 |
| Babler, A | 1 |
| Schmitz, C | 1 |
| Buescher, A | 1 |
| Herrmann, M | 1 |
| Gremse, F | 1 |
| Gorgels, T | 1 |
| Floege, J | 1 |
| Jahnen-Dechent, W | 1 |
| Boyce, AM | 1 |
| Gafni, RI | 1 |
| Ferreira, CR | 1 |
| Yan, JF | 1 |
| Qin, WP | 1 |
| Xiao, BC | 1 |
| Wan, QQ | 1 |
| Tay, FR | 1 |
| Niu, LN | 1 |
| Jiao, K | 1 |
| Engelke, UFH | 1 |
| Rhee, K | 1 |
| Williams, CJ | 1 |
| Sundberg, JP | 1 |
| Wevers, RA | 1 |
| Tomlinson, RE | 1 |
| Shimada, BK | 1 |
| Pomozi, V | 2 |
| Zoll, J | 2 |
| Kuo, S | 1 |
| Martin, L | 2 |
| Le Saux, O | 2 |
| Hsu, VM | 1 |
| Kozák, E | 1 |
| Bocskai, M | 1 |
| Schlesinger, N | 1 |
| Rosenthal, A | 1 |
| McClure, ST | 1 |
| Kovács, L | 1 |
| Bálint, L | 1 |
| Szamosi, S | 1 |
| Szücs, G | 1 |
| Carns, M | 1 |
| Aren, K | 1 |
| Goldberg, I | 1 |
| Váradi, A | 2 |
| Varga, J | 1 |
| Brampton, C | 1 |
| Calio, B | 1 |
| Pham, K | 1 |
| Owens, JB | 1 |
| Marh, J | 1 |
| Moisyadi, S | 1 |
| Bauer, C | 1 |
| Erdmann, J | 1 |
| Aherrahrou, Z | 1 |
| Smith, ER | 1 |
| Ford, ML | 1 |
| Tomlinson, LA | 1 |
| Bodenham, E | 1 |
| McMahon, LP | 1 |
| Farese, S | 1 |
| Rajkumar, C | 1 |
| Holt, SG | 1 |
| Pasch, A | 1 |
| Boraldi, F | 1 |
| Annovi, G | 1 |
| Bartolomeo, A | 1 |
| Quaglino, D | 1 |
| Rattazzi, M | 1 |
| Bertacco, E | 1 |
| Iop, L | 1 |
| D'Andrea, S | 1 |
| Puato, M | 1 |
| Buso, G | 1 |
| Causin, V | 1 |
| Gerosa, G | 1 |
| Faggin, E | 1 |
| Pauletto, P | 1 |
| Rathan, S | 1 |
| Yoganathan, AP | 1 |
| O'Neill, CW | 1 |
| Orriss, IR | 1 |
| Arnett, TR | 1 |
| Russell, RG | 2 |
| Moochhala, SH | 1 |
| FLEISCH, H | 2 |
| BISAZ, S | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Employment Retention Issues for Patient With Pseudoxanthoma Elasticum[NCT05246189] | 99 participants (Actual) | Observational | 2022-04-07 | Completed | |||
| The Effect of Orally Administered Pyrophosphate on Calcinosis Formation in Systematic Sclerosis[NCT04966416] | 60 participants (Anticipated) | Interventional | 2023-08-01 | Not yet recruiting | |||
| Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)[NCT03813550] | 20 participants (Anticipated) | Interventional | 2019-01-21 | Recruiting | |||
| Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity[NCT02241109] | 200 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)[NCT04660461] | Phase 4 | 20 participants (Anticipated) | Interventional | 2020-02-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for diphosphoric acid and Calcinosis
| Article | Year |
|---|---|
Inorganic Pyrophosphate Deficiency Syndromes and Potential Treatments for Pathologic Tissue Calcification.
Topics: Ankylosis; Calcinosis; Choristoma; Diphosphates; Humans; Pseudoxanthoma Elasticum; Syndrome; Vascula | 2022 |
Generalized Arterial Calcification of Infancy: New Insights, Controversies, and Approach to Management.
Topics: Adenosine Monophosphate; Bone Density Conservation Agents; Calcinosis; Cardiovascular Agents; Chelat | 2020 |
Pathological calcification in osteoarthritis: an outcome or a disease initiator?
Topics: Apoptosis; Bursa, Synovial; Calcinosis; Calcium; Cartilage; Chondrocytes; Collagen; Diphosphates; Ex | 2020 |
ABCC6, Pyrophosphate and Ectopic Calcification: Therapeutic Solutions.
Topics: 5'-Nucleotidase; Animals; ATP-Binding Cassette Transporters; Calcification, Physiologic; Calcinosis; | 2021 |
Pyrophosphate: a key inhibitor of mineralisation.
Topics: Adenosine Triphosphate; Animals; Calcification, Physiologic; Calcinosis; Diphosphates; Gene Expressi | 2016 |
Extracellular pyrophosphate in the kidney: how does it get there and what does it do?.
Topics: Animals; Aquaporin 2; Calcinosis; Cilia; Diphosphates; Humans; Kidney; Membrane Transport Proteins; | 2012 |
17 other studies available for diphosphoric acid and Calcinosis
| Article | Year |
|---|---|
The Mineralization Regulator ANKH Mediates Cellular Efflux of ATP, Not Pyrophosphate.
Topics: Adenosine Triphosphate; Animals; Bone and Bones; Calcification, Physiologic; Calcinosis; Diphosphate | 2022 |
A new enzymatic assay to quantify inorganic pyrophosphate in plasma.
Topics: Adenosine Triphosphate; Animals; Calcinosis; Diphosphates; Humans; Luciferases, Firefly; Rats | 2023 |
A new enzymatic assay to quantify inorganic pyrophosphate in plasma.
Topics: Adenosine Triphosphate; Animals; Calcinosis; Diphosphates; Humans; Luciferases, Firefly; Rats | 2023 |
A new enzymatic assay to quantify inorganic pyrophosphate in plasma.
Topics: Adenosine Triphosphate; Animals; Calcinosis; Diphosphates; Humans; Luciferases, Firefly; Rats | 2023 |
A new enzymatic assay to quantify inorganic pyrophosphate in plasma.
Topics: Adenosine Triphosphate; Animals; Calcinosis; Diphosphates; Humans; Luciferases, Firefly; Rats | 2023 |
A new enzymatic assay to quantify inorganic pyrophosphate in plasma.
Topics: Adenosine Triphosphate; Animals; Calcinosis; Diphosphates; Humans; Luciferases, Firefly; Rats | 2023 |
A new enzymatic assay to quantify inorganic pyrophosphate in plasma.
Topics: Adenosine Triphosphate; Animals; Calcinosis; Diphosphates; Humans; Luciferases, Firefly; Rats | 2023 |
A new enzymatic assay to quantify inorganic pyrophosphate in plasma.
Topics: Adenosine Triphosphate; Animals; Calcinosis; Diphosphates; Humans; Luciferases, Firefly; Rats | 2023 |
A new enzymatic assay to quantify inorganic pyrophosphate in plasma.
Topics: Adenosine Triphosphate; Animals; Calcinosis; Diphosphates; Humans; Luciferases, Firefly; Rats | 2023 |
A new enzymatic assay to quantify inorganic pyrophosphate in plasma.
Topics: Adenosine Triphosphate; Animals; Calcinosis; Diphosphates; Humans; Luciferases, Firefly; Rats | 2023 |
Microcalcification and
Topics: Amyloidosis; Calcinosis; Cardiomyopathies; Diphosphates; Humans; Immunoglobulin Light-chain Amyloido | 2023 |
Patient-Reported Outcomes in Calcium Pyrophosphate Deposition Disease Compared to Gout and Osteoarthritis.
Topics: Aged; Calcinosis; Calcium Pyrophosphate; Chondrocalcinosis; Female; Gout; Humans; Male; Osteoarthrit | 2023 |
Asfotase alfa improved skeletal mineralization and fracture healing in a child with MCAHS.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Diseases, Metabolic; Calcinosis; Calcium; Calcium, Dietar | 2023 |
ATP-based therapy prevents vascular calcification and extends longevity in a mouse model of Hutchinson-Gilford progeria syndrome.
Topics: Adenosine Triphosphate; Alkaline Phosphatase; Animals; Antigens, CD; Aortic Diseases; Apyrase; Calci | 2019 |
Microvasculopathy and soft tissue calcification in mice are governed by fetuin-A, magnesium and pyrophosphate.
Topics: alpha-2-HS-Glycoprotein; alpha-Fetoproteins; Animals; Calcinosis; Diphosphates; Disease Models, Anim | 2020 |
The membrane protein ANKH is crucial for bone mechanical performance by mediating cellular export of citrate and ATP.
Topics: Adenosine Triphosphate; Animals; Bone and Bones; Bone Development; Calcinosis; Cell Differentiation; | 2020 |
Inorganic pyrophosphate is reduced in patients with systemic sclerosis.
Topics: Adult; Aged; Calcinosis; Diphosphates; Female; Humans; Male; Middle Aged; Scleroderma, Systemic | 2022 |
Pyrophosphate Supplementation Prevents Chronic and Acute Calcification in ABCC6-Deficient Mice.
Topics: Acute Disease; Animals; ATP-Binding Cassette Transporters; Calcinosis; Chronic Disease; Diphosphates | 2017 |
Serum calcification propensity predicts all-cause mortality in predialysis CKD.
Topics: Aged; Aged, 80 and over; alpha-2-HS-Glycoprotein; Arteriosclerosis; Biomarkers; Calcinosis; Calcium | 2014 |
Fibroblasts from patients affected by Pseudoxanthoma elasticum exhibit an altered PPi metabolism and are more responsive to pro-calcifying stimuli.
Topics: Adult; Alkaline Phosphatase; Calcinosis; Calcium; Calcium-Binding Proteins; Diphosphates; DNA Primer | 2014 |
Extracellular pyrophosphate is reduced in aortic interstitial valve cells acquiring a calcifying profile: implications for aortic valve calcification.
Topics: Adenosine Triphosphate; Alkaline Phosphatase; Animals; Aorta; Aortic Valve; Aortic Valve Stenosis; C | 2014 |
The role of inorganic pyrophosphate in aortic valve calcification.
Topics: Alkaline Phosphatase; Animals; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Diphosphates; Etidro | 2014 |
[Isolation from the plasma of pyrophosphate, an inhibitor of calcification].
Topics: Calcification, Physiologic; Calcinosis; Diphosphates; Humans | 1962 |
Isolation from urine of pyrophosphate, a calcification inhibitor.
Topics: Calcification, Physiologic; Calcinosis; Calcium; Calcium, Dietary; Diphosphates; Humans; Urine | 1962 |
EXCRETION OF INORGANIC PYROPHOSPHATE IN HYPOPHOSPHATASIA.
Topics: Alkaline Phosphatase; Calcification, Physiologic; Calcinosis; Chromatography; Diphosphates; Fluids a | 1965 |